To determine short- and long-term outcomes of major hepatectomy in patients with downstaged colorectal liver metastases considered initially unresectable (IU).
Improvements in both surgical technique and efficacy of chemotherapy have increased the rate of resection for IU colorectal liver metastases. The outcome of these patients needs to be reassessed.
From 2000 to 2011, 257 patients underwent major hepatectomy for colorectal liver metastases. Of these, 87 (34%) IU patients required portal vein occlusion after chemotherapy downstaging. Patients requiring less than 12 cycles and 12 or more cycles of chemotherapy before resection were defined as fast responders and slow responders, respectively.
Compared with fast responders, slow responders had increased mortality (0% vs 19%, P = 0.003) and major morbidity rates (20% vs 55%, P < 0.001) despite almost identical tumor characteristics and similar procedures. In multivariate analysis, the only factor associated with increased major morbidity was the existence of a number of chemotherapy cycles of 12 or more (hazard ratio [HR]: 5.32, confidence interval [CI]: 1.69–16.7, P = 0.004). One-, 3-, and 5-year disease-free survival rates for the entire population were 48%, 17.5%, and 13%, respectively. Multivariate analysis found that slow responders (HR: 2.89, CI: 1.67–5.04, P < 0.001) and patients without adjuvant chemotherapy (HR: 2.38, CI: 1.33–4.35, P = 0.004) had a significantly decreased disease-free survival. All slow responders postoperatively recurred within 3 years.
Liver resection in slow responders, that is, IU patients requiring 12 or more chemotherapy cycles and portal vein occlusion to achieve resectability, is associated with poor short- and long-term outcomes. These patients would probably benefit from more conservative strategies.
Supplemental Digital Content is Available in the Text.Major liver resection after portal vein occlusion and more than 12 cycles of neoadjuvant chemotherapy for colorectal liver metastases in patients considered initially unresectable were associated with poor short- and long-term outcomes.
Departments of *HPB Surgery & Liver Transplantation and
†Oncology, Beaujon Hospital, Clichy, France; Assistance Publique-Hôpitaux de Paris, University Paris 7
‡Department of Oncology, Clinique Pasteur, Evreux, France.
Reprints: Jacques Belghiti, MD, Department of HPB Surgery & Liver Transplantation, Beaujon Hospital, 100 Bd du Général Leclerc, 92110 Clichy, France. E-mail: firstname.lastname@example.org.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.annalsofsurgery.com).
Disclosure: The authors declare that they have nothing to disclose.